Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem ...

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

Vertex Pharmaceuticals (NASDAQ:VRTX) announced Friday a reimbursement agreement with England’s National Health Service (NHS) ...

NHS patients with sickle cell disease will be able to benefit from a groundbreaking gene-editing treatment that offers the prospect of a cure for the condition. The one-off gene therapy, known as ...

Everything you need to know about agonising sickle cell disease and the ‘revolutionary’ new DNA therapy that's being rolled ...

Crucially foetal haemoglobin is not affected by sickle cell disease, so Crispr acts by dampening ... transfusion-dependent beta thalassemia. It is already being given to patients in other ...

One sickle cell patient told ITV News the new gene therapy being rolled out for use on the NHS means they "finally have something to look towards". | ITV National News ...

The Exa-cel gene therapy treatment is at the forefront of medical technology. It takes the person’s DNA and “edits” out the faulty sickle gene. It’s expensive, too. According to the manufacturer, ...

"This type of gene editing should also allow for the treatment of diseases whose origin is not genetic or whose origin cannot ...

Investor enthusiasm about technology and growth stocks ... s interest in improving on Casgevy, its CRISPR medicine for sickle cell and beta thalassemia.

A £1.65 million treatment has been approved for use for some NHS patients, offering hope of a cure to those with an inherited ...